NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

So what’s the logical conclusion? MHRA approval isn’t the start of commercialization for NWBO.

I find what you have posted interesting, but with one problem. The logic is too strong. If as you assume

The latest NICE response confirms that NWBO hasn’t even submitted evidence for reimbursement assessment, let alone entered any pilot program for early access or collaboration. That’s not just a delay it’s a signal. Combine that with the fact that NWBO hasn’t staffed up in the UK for commercial sales, not through themselves and not via Advent. No commercial team. No distribution hires. No sales infrastructure. Nothing.

This is telling. NWBO has repeatedly stated that they plan to “franchise” DCVax-L. In other words, they don’t plan to sell it themselves — they intend to hand it off, either through licensing or outright sale, to a pharmaceutical partner who will handle market entry.

then they must already have a deal completed and in hand with all but the signature on the bottom line. Anything short of that, would leave them with the possibly of no deal happening, and that leaving them totally unprepared, without retaining a marketing force to prepare for the commercialization following approval1 So which is it? Is the deal done or are they unprepared for approval and commercialization?